ClinicalTrials.gg
CompletedNCT00721734Updated May 2, 2017Results posted

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

A Phase 2 interventional study of Carfilzomib in Multiple Myeloma and Renal Insufficiency, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
60th of 113
50 · median 54
Started
2008
with 1 other
Phase 2
50 of 113
6 open now
Registered
6th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 60th largest by enrollment, is one of 2 that started in 2008, is one of 50 in phase 2, and was the 6th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).

03

Conditions studied

  • Multiple Myeloma
  • Renal Insufficiency

Keywords

  • Myeloma
  • Renal Insufficiency
  • Proteasome
  • Hematological
  • carfilzomib
  • PR-171
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written in accordance with federal, local, and institutional guidelines
  2. Males and females ≥ 18 years of age
  3. Multiple Myeloma
  4. Documented or progressive disease (PD) after receiving at least two prior treatment regimens (induction therapy with stem cell transplant and maintenance is considered a single regimen), and must have achieved a minimal response or better to at least one of the regimens
  5. Current , as indicated by one or more of the following:

    • Serum M-protein ≥ 0.5 g/dL
    • Urine M-protein ≥ 200 mg/24 hours
    • Serum Free Light Chain (FLC) assay: Involved FLC level ≥ 10 mg/dL provided serum FLC ratio is abnormal
  6. of more than three months
  7. (ECOG) Performance Status 0-2
  8. Adequate hepatic function, with \< 2 times the (ULN) and (ALT) \< 3 times ULN
  9. Total white blood cell (WBC) count ≥ 2,000/mm³
  10. (ANC) ≥ 1,000/mm³
  11. ≥ 7 gm/dL

    • Subjects may receive red blood cell (RBC) transfusions or supportive care with erythropoietin or darbepoetin in accordance with institutional guidelines
  12. count ≥ 30,000/ mm³
  13. Female subjects of must have a negative serum pregnancy test within seven days of the first dose and agree to use dual methods of during and for 3 months following last dose of drug. Post menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from a pregnancy test
  14. Male subjects must use an effective barrier method of contraception during study and for three months following the last dose if sexually active with a female of child-bearing potential

Exclusion criteria

Exclusion Criteria:

  1. therapy in a dose equivalent to prednisone ≥ 20 mg/day within 14 days prior to first dose of study drug
  2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  3. Plasma cell leukemia
  4. Chemotherapy with approved or investigative anticancer therapeutics, including steroid therapy dose as defined above, within 14 days prior to first dose of study drug or antibody therapy within 6 weeks prior to first dose of study drug
  5. Radiation therapy or immunotherapy within 3 weeks prior to first dose; localized radiation therapy within 1 week prior to first dose
  6. Participation in an therapeutic study within 14 days prior to first dose of study drug
  7. Prior carfilzomib treatment
  8. Pregnant or lactating females
  9. Major surgery within 3 weeks prior to first dose of study drug
  10. Congestive heart failure ( Class III to IV), symptomatic ischemia, conduction abnormalities or myocardial infarction in the three months prior to first dose of study drug
  11. Uncontrolled hypertension
  12. Recent history of acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose of study drug
  13. Known or suspected (HIV) infection, known HIV seropositivity
  14. Active hepatitis A, B, or C infection
  15. Other within the past 3 years except a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate cancer \< Gleason Grade 7 with stable prostate specific antigen (PSA) levels
  16. Any medical or psychiatric disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give
  17. Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days prior to enrollment
  18. Subjects in whom the required program of oral hydration and intravenous fluid hydration is , e.g., due to preexisting pulmonary or cardiac impairment
  19. Subjects with pleural effusions requiring routine thoracentesis or ascites requiring routine paracentesis
  20. Subjects with a known contraindication to receiving dexamethasone or allopurinol
  21. Receipt of granulocyte- and granulocyte/ macrophage- colony stimulating factor (G-CSF and GM-CSF) within 1 week prior to first dose of study drug
  22. Receipt of pegylated G-CSF within 2 weeks prior to first dose of study drug
  23. RBC and transfusions within 7 days prior to first dose of study drug
  24. Subjects with known or suspected cardiac amyloidosis
  25. Subjects with myelodysplastic syndrome
  26. Subjects undergoing peritoneal dialysis
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Carfilzomib

    Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles. If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles.

    Drug: Carfilzomib

Interventions

  • Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.

    Also known as: PR-171, Kyprolis®

06

What researchers measure

Primary outcomes

  1. Clearance (CL) of Carfilzomib on Day 1 of Cycle 1

    Plasma concentrations of carfilzomib was determined by a validated liquid chromatography tandem mass spectrometry (LC MS/MS) method. The lower limit of quantitation (LLOQ) was 0.300 ng/mL. Concentration values that were below the LLOQ (BLQ) were set to zero. Pharmacokinetic (PK) parameters were calculated from the individual plasma concentrations of carfilzomib using a noncompartmental method.

    Time frame: Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

Secondary outcomes

  1. Clearance (CL) of Carfilzomib on Day 15 of Cycle 1

    Time frame: Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  2. Clearance (CL) of Carfilzomib on Day 15 of Cycle 2

    Time frame: Cycle 2, Day 15, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  3. Maximum Observed Plasma Concentration of Carfilzomib on Day 1 of Cycle 1

    Time frame: Cycle 1, Day 1, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  4. Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 1

    Time frame: Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  5. Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 2

    Time frame: Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  6. Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 1 of Cycle 1

    Time frame: Cycle 1, Day 1, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  7. Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 1

    Time frame: Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  8. Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 2

    Time frame: Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  9. Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 1 of Cycle 1

    Time frame: Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  10. Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 1

    Time frame: Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  11. Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 2

    Time frame: Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.

  12. Percentage of Carfilzomib Excreted Via Renal Elimination on Day 1 of Cycle 1

    The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose.

    Time frame: Cycle 1, Day 1, 0-5 and 5-24 hours post-dose

  13. Percentage of Carfilzomib Excreted Via Renal Elimination on Day 15 of Cycle 1

    The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose.

    Time frame: Cycle 1, Day 15, 0-5 and 5-24 hours post-dose

  14. Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 1 of Cycle 1

    The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose.

    Time frame: Cycle 1, Day 1, 0-5 and 5-24 hours post-dose

  15. Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 15 of Cycle 1

    The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose.

    Time frame: Cycle 1, Day 15, 0-5 and 5-24 hours post-dose

  16. Plasma Protein Binding (PPB) of Carfilzomib

    The plasma protein binding (PPB) of carfilzomib in plasma samples was determined using a rapid equilibrium dialysis (RED) device. Data are averages of the 3 time points (Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15).

    Time frame: End of injection and 5 minutes post-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15

  17. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per the International Uniform Response Criteria for Multiple Myeloma. sCR: CR as defined below plus normal serum free light chain (sFLC) ratio and absence of clonal plasma cells in bone marrow by immunohistochemistry or immunofluorescence; CR: absence of M-protein in serum and urine confirmed by immunofixation and \< 5% plasma cells in the bone marrow; VGPR: serum and urine M-proteins detectable by immunofixation, but not by electrophoresis or a ≥ 90% reduction in serum M-protein from baseline, plus a urine M-protein level of \< 100 mg/24 hours; PR: reduction of M-protein in serum of ≥ 50% and in urine of ≥ 90% from baseline. If serum and urine M-protein were not measureable at baseline, a ≥ 50% decrease in the difference between involved and uninvolved sFLC levels from baseline.

    Time frame: From first dose until 30 days after the last dose; median duration of treatment across all groups was 121 days.

  18. Clinical Benefit Rate (CBR)

    Clinical benefit rate is defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89% from baseline, maintained for at least 6 weeks.

    Time frame: From first dose until 30 days after the last dose; median duration of treatment across all groups was 121 days.

  19. Duration of Response

    Duration of Response is defined as the time from first evidence of PR or better to confirmation of disease progression or death. Progressive disease was defined as any of the following: * An increase of more than 25% from nadir in any one of the following: * M-protein in serum (the absolute increase had to be ≥ 0.5 g/dL); * Urine (the absolute increase had to be ≥ 200 mg/24 hours); * The difference between involved and uninvolved sFLC (the absolute increase in the concentration of involved light chain had to be \> 10 mg/dL); * ≥ 10% bone marrow infiltration by plasma cells; * Increased size of pre-existing bone lesions or plasmacytomas or new bone lesions or plasmacytomas. Median duration of response was estimated using the Kaplan-Meier method.

    Time frame: Participants were followed for disease progression for up to 2 years.

  20. Time to Progression (TTP)

    Time to Progression is defined as the time from first dose of carfilzomib to disease progression. Median TTP was estimated using Kaplan-Meier methods.

    Time frame: Participants were followed for disease progression for up to 2 years.

07

Results

Posted Dec 9, 2015

Participant flow

This study enrolled patients with multiple myeloma (MM) who had relapsed or progressive disease (PD) after at least 1 (original protocol) or 2 (following protocol Amendment 1) prior therapeutic treatments or regimens. Five groups of MM patients, representing different levels of renal function, were evaluated.

Participant flow — Overall Study
MilestoneCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Started12121088
Completed40222
Not completed812866
Withdrew: Progressive disease310452
Withdrew: Adverse event31403
Withdrew: Withdrawal by subject21001
Withdrew: Other00010

Outcome measures

PrimaryClearance (CL) of Carfilzomib on Day 1 of Cycle 1

Plasma concentrations of carfilzomib was determined by a validated liquid chromatography tandem mass spectrometry (LC MS/MS) method. The lower limit of quantitation (LLOQ) was 0.300 ng/mL. Concentration values that were below the LLOQ (BLQ) were set to zero. Pharmacokinetic (PK) parameters were calculated from the individual plasma concentrations of carfilzomib using a noncompartmental method.

Time frame:
Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Mean · liters/hour
Clearance (CL) of Carfilzomib on Day 1 of Cycle 1
liters/hourCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Clearance (CL) of Carfilzomib on Day 1 of Cycle 1151 ± 79.3113 ± 40.7288 ± 264170 ± 58.4170 ± 60.2
Statistical analysis
  • Carfilzomib - Normal RF vs Carfilzomib - Mild RI vs Carfilzomib - Moderate RI vs Carfilzomib - Severe RI · Regression, Linear · p = 0.4114 · Slope: -0.607 · 95% CI -2.129 to 0.914
SecondaryClearance (CL) of Carfilzomib on Day 15 of Cycle 1
Time frame:
Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Mean · liters/hour
Clearance (CL) of Carfilzomib on Day 15 of Cycle 1
liters/hourCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Clearance (CL) of Carfilzomib on Day 15 of Cycle 1660 ± 1134115 ± 34.7119 ± 16.5110 ± NA114 ± 61.2
SecondaryClearance (CL) of Carfilzomib on Day 15 of Cycle 2
Time frame:
Cycle 2, Day 15, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Mean · liters/hour
Clearance (CL) of Carfilzomib on Day 15 of Cycle 2
liters/hourCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Clearance (CL) of Carfilzomib on Day 15 of Cycle 2——679 ± NA46.6 ± NA—
SecondaryMaximum Observed Plasma Concentration of Carfilzomib on Day 1 of Cycle 1
Time frame:
Cycle 1, Day 1, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration of Carfilzomib on Day 1 of Cycle 1
ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Maximum Observed Plasma Concentration of Carfilzomib on Day 1 of Cycle 12077 ± 91.41623 ± 1611840 ± 92.41231 ± 1391539 ± 92.7
SecondaryMaximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 1
Time frame:
Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 1
ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 11768 ± 1792406 ± 52.32627 ± 31.81914 ± 99.83236 ± 34.4
SecondaryMaximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 2
Time frame:
Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 2
ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 2——244 ± NA3064 ± 3.9—
SecondaryArea Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 1 of Cycle 1
Time frame:
Cycle 1, Day 1, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 1 of Cycle 1
hr*ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 1 of Cycle 1233 ± 51.6241 ± 32.4145 ± 111172 ± 35.6193 ± 55.2
SecondaryArea Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 1
Time frame:
Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 1
hr*ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 1127 ± 240236 ± 44.3257 ± 10.9218 ± NA272 ± 46.4
SecondaryArea Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 2
Time frame:
Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 2
hr*ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 2——48.6 ± NA579 ± NA—
SecondaryArea Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 1 of Cycle 1
Time frame:
Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 1 of Cycle 1
hr*ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 1 of Cycle 1187 ± 75.3194 ± 67.6199 ± 91.3135 ± 65.5195 ± 65.3
SecondaryArea Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 1
Time frame:
Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 1
hr*ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 1159 ± 186289 ± 58.5371 ± 55.2343 ± 53.1264 ± 41.7
SecondaryArea Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 2
Time frame:
Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 2
hr*ng/mLCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 2——47.3 ± NA345 ± 83.6—
SecondaryPercentage of Carfilzomib Excreted Via Renal Elimination on Day 1 of Cycle 1

The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose.

Time frame:
Cycle 1, Day 1, 0-5 and 5-24 hours post-dose
Reported as:
Mean · percentage of carfilzomib dose
Percentage of Carfilzomib Excreted Via Renal Elimination on Day 1 of Cycle 1
percentage of carfilzomib doseCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Percentage of Carfilzomib Excreted Via Renal Elimination on Day 1 of Cycle 10.490 ± 0.3160.429 ± 0.2710.160 ± 0.1010.226 ± 0.0921—
SecondaryPercentage of Carfilzomib Excreted Via Renal Elimination on Day 15 of Cycle 1

The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose.

Time frame:
Cycle 1, Day 15, 0-5 and 5-24 hours post-dose
Reported as:
Mean · percentage of carfilzomib dose
Percentage of Carfilzomib Excreted Via Renal Elimination on Day 15 of Cycle 1
percentage of carfilzomib doseCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Percentage of Carfilzomib Excreted Via Renal Elimination on Day 15 of Cycle 10.446 ± 0.3570.428 ± 0.2620.202 ± 0.1160.168 ± 0.0670—
SecondaryPercentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 1 of Cycle 1

The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose.

Time frame:
Cycle 1, Day 1, 0-5 and 5-24 hours post-dose
Reported as:
Mean · percentage of carfilzomib dose
Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 1 of Cycle 1
percentage of carfilzomib doseCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
M1433.1 ± 13.125.0 ± 4.8121.7 ± 7.5919.2 ± 4.36—
M151.93 ± 1.121.42 ± 0.3140.776 ± 0.3870.578 ± 0.230—
SecondaryPercentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 15 of Cycle 1

The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose.

Time frame:
Cycle 1, Day 15, 0-5 and 5-24 hours post-dose
Reported as:
Mean · percentage of carfilzomib dose
Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 15 of Cycle 1
percentage of carfilzomib doseCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
M1430.6 ± 11.627.0 ± 8.4722.0 ± 6.8917.0 ± 4.67—
M151.91 ± 1.031.55 ± 0.6020.856 ± 0.3770.475 ± 0.249—
SecondaryPlasma Protein Binding (PPB) of Carfilzomib

The plasma protein binding (PPB) of carfilzomib in plasma samples was determined using a rapid equilibrium dialysis (RED) device. Data are averages of the 3 time points (Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15).

Time frame:
End of injection and 5 minutes post-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15
Reported as:
Mean · percentage of carfilzomib bound
Plasma Protein Binding (PPB) of Carfilzomib
percentage of carfilzomib boundCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
End of Injection97.8 ± 0.697.6 ± 1.598.4 ± 0.498.2 ± 0.597.6 ± 0.7
5 minutes after injection98.1 ± 0.597.6 ± 1.698.2 ± 1.598.1 ± 0.898.2 ± 0.4
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per the International Uniform Response Criteria for Multiple Myeloma. sCR: CR as defined below plus normal serum free light chain (sFLC) ratio and absence of clonal plasma cells in bone marrow by immunohistochemistry or immunofluorescence; CR: absence of M-protein in serum and urine confirmed by immunofixation and \< 5% plasma cells in the bone marrow; VGPR: serum and urine M-proteins detectable by immunofixation, but not by electrophoresis or a ≥ 90% reduction in serum M-protein from baseline, plus a urine M-protein level of \< 100 mg/24 hours; PR: reduction of M-protein in serum of ≥ 50% and in urine of ≥ 90% from baseline. If serum and urine M-protein were not measureable at baseline, a ≥ 50% decrease in the difference between involved and uninvolved sFLC levels from baseline.

Time frame:
From first dose until 30 days after the last dose; median duration of treatment across all groups was 121 days.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Overall Response Rate (ORR)18.2 (2.3 to 51.8)27.3 (6.0 to 61.0)22.2 (2.8 to 60.0)25.0 (3.2 to 65.1)37.5 (8.5 to 75.5)
SecondaryClinical Benefit Rate (CBR)

Clinical benefit rate is defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89% from baseline, maintained for at least 6 weeks.

Time frame:
From first dose until 30 days after the last dose; median duration of treatment across all groups was 121 days.
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Clinical Benefit Rate (CBR)27.3 (6.0 to 61.0)36.4 (10.9 to 69.2)22.2 (2.8 to 60.0)37.5 (8.5 to 75.5)37.5 (8.5 to 75.5)
SecondaryDuration of Response

Duration of Response is defined as the time from first evidence of PR or better to confirmation of disease progression or death. Progressive disease was defined as any of the following: * An increase of more than 25% from nadir in any one of the following: * M-protein in serum (the absolute increase had to be ≥ 0.5 g/dL); * Urine (the absolute increase had to be ≥ 200 mg/24 hours); * The difference between involved and uninvolved sFLC (the absolute increase in the concentration of involved light chain had to be \> 10 mg/dL); * ≥ 10% bone marrow infiltration by plasma cells; * Increased size of pre-existing bone lesions or plasmacytomas or new bone lesions or plasmacytomas. Median duration of response was estimated using the Kaplan-Meier method.

Time frame:
Participants were followed for disease progression for up to 2 years.
Reported as:
Median · months
Duration of Response
monthsCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Duration of ResponseNA (2.0 to NA)NA (4.2 to NA)14.8 (2.3 to 27.4)NA (7.9 to NA)7.9 (6.5 to 8.5)
SecondaryTime to Progression (TTP)

Time to Progression is defined as the time from first dose of carfilzomib to disease progression. Median TTP was estimated using Kaplan-Meier methods.

Time frame:
Participants were followed for disease progression for up to 2 years.
Reported as:
Median · months
Time to Progression (TTP)
monthsCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
Time to Progression (TTP)4.4 (2.8 to 9.2)5.6 (0.5 to 7.9)2.8 (1.0 to 29.2)9.6 (1.0 to 11.8)6.5 (2.8 to 11.3)

Adverse events

Collected over From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 121 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carfilzomib - Normal RF—5/12 (41.7%)12/12 (100%)
Carfilzomib - Mild RI—8/12 (66.7%)12/12 (100%)
Carfilzomib - Moderate RI—10/10 (100%)10/10 (100%)
Carfilzomib - Severe RI—6/8 (75%)8/8 (100%)
Carfilzomib - Dialysis—8/8 (100%)8/8 (100%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
PneumoniaInfections and infestations2/122/124/102/80/8
Disease progressionGeneral disorders0/123/120/101/83/8
Mental status changesPsychiatric disorders0/121/123/100/80/8
Cardiac failure congestiveCardiac disorders1/120/120/102/80/8
DehydrationMetabolism and nutrition disorders0/120/122/102/80/8
Renal failure acuteRenal and urinary disorders0/121/121/102/80/8
DyspnoeaRespiratory, thoracic and mediastinal disorders0/121/120/100/82/8
Respiratory failureRespiratory, thoracic and mediastinal disorders0/120/121/100/82/8
InfluenzaInfections and infestations0/120/122/100/81/8
Renal failureRenal and urinary disorders0/120/122/100/80/8
Most frequent other events
Showing 10 of 255
Most frequent other events
EventCarfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - Dialysis
FatigueGeneral disorders9/129/126/104/84/8
AnaemiaBlood and lymphatic system disorders6/127/127/105/85/8
ThrombocytopeniaBlood and lymphatic system disorders4/126/125/103/85/8
NauseaGastrointestinal disorders6/124/126/101/84/8
LymphopeniaBlood and lymphatic system disorders4/124/122/102/84/8
Abdominal painGastrointestinal disorders1/122/122/100/84/8
ConstipationGastrointestinal disorders3/126/125/102/83/8
DiarrhoeaGastrointestinal disorders5/126/125/102/84/8
PainGeneral disorders0/123/124/100/84/8
PyrexiaGeneral disorders3/122/123/100/84/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Carfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - DialysisTotal
<=18 years000000
Between 18 and 65 years6841726
>=65 years6467124
Age, Continuous
Age, Continuous(years)Carfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - DialysisTotal
Mean64.5 ± 5.7063.5 ± 7.8566.2 ± 9.6573.0 ± 8.2356.0 ± 7.9164.6 ± 9.01
Sex: Female, Male
Sex: Female, Male(Participants)Carfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - DialysisTotal
Female4833422
Male8475428
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Carfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - DialysisTotal
African American2241211
Asian/Pacific Islander020013
Caucasian10867536
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Carfilzomib - Normal RFCarfilzomib - Mild RICarfilzomib - Moderate RICarfilzomib - Severe RICarfilzomib - DialysisTotal
0 (Fully active)420208
1 (Restrictive but ambulatory)8991532
2 (Ambulatory but unable to work)0115310
08

Study locations

5 sites
  • University of California- San Francisco
    San Francisco, California 94143, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Cornell University
    New York, New York 10021, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2008
First posted
Jul 24, 2008
Start
Nov 2008
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Dec 9, 2015
Last update
May 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00721734
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 24, 2008
Start date
Nov 2008
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Dec 9, 2015
Last update
May 2, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion